Supplementary Figure S1 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
Paraskevi Miltiades(Democritus University of Thrace), Ιoannis Kotsianidis(Democritus University of Thrace), Christos K. Kontos(National and Kapodistrian University of Athens), Evdoxia Hatjiharissi(Boston University), Sotirios G. Papageorgiou(University General Hospital Attikon), Sofia Vakalopoulou(Aristotle University of Thessaloniki), Evangelia Nakou(Democritus University of Thrace), Panagiotis G. Adamopoulos(National and Kapodistrian University of Athens), Maria Papaioannou(Children's Nutrition Research Center at Baylor College of Medicine), Helen Α. Papadaki(University of Crete), Theodoros P. Vassilakopoulos(National and Kapodistrian University of Athens), Andreas Scorilas(National and Kapodistrian University of Athens), Constantinos Tsatalas(Democritus University of Thrace), Vassilia Garypidou(Aristotle University of Thessaloniki), Emmanuil Spanoudakis(Democritus University of Thrace), Eleftheria Lamprianidou(Democritus University of Thrace), Vassiliki Pappa(University General Hospital Attikon), Athanasios Galanopoulos
Cited by 0
Related Papers
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2
|Nature Genetics|2003|389
Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide
|Journal of Clinical Oncology|2007|279
High serum cholesterol levels in persons with 'high-normal' TSH levels: should one extend the definition of subclinical hypothyroidism?
|European Journal of Endocrinology|1998|164